Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of metabolic syndrome. It encompasses a spectrum of diseases that range from simple steatosis to nonalcoholic steatohepatitis (NASH), cirrhosis and hepatocellular carcinoma. Over the next decade, health experts expect NASH to become the leading cause of liver transplants.

Currently, there are no FDA-approved treatments for NASH. A diverse set of disease drivers including genetics, environmental cues, microbiota metabolism and lifestyle influences come together resulting in an uncertain natural history of NAFLD/NASH. The constellation of risk factors for NASH has spawned a remarkable array of targets, and there is a significant need to bring the most effective treatments through development and to patients quickly.

Metabolomics provides a comprehensive picture of the metabolome and maps metabolites to their key biochemical pathways. Metabolon's Precision Metabolomics technology is a mass spectrometry-based method that allows for the identification of over 1,000 small molecule compounds in a single sample. By simultaneously surveying diverse metabolic pathways in a single sample, Precision Metabolomics provides a holistic assessment of NAFLD/NASH complexity.

This webinar reviews applications of this technology in NASH research, including a recent study designed and carried out by Dr. Jamie Bates of Gilead Sciences. It also highlights new tools Metabolon currently offers NAFLD/NASH liver disease researchers.

Learning Objectives:

  • Technology overview
  • Highlight the platform findings from Gilead's Acetyl CoA Carboxylase inhibitor in a mouse model
  • Metabolomics from discovery to the clinic
  • Metabolon as a translational resource

Jamie Bates, PhD
Research Scientist II
Gilead Sciences

Kari Wong, PhD
Senior Study Director